Bactericidal activities of DU-6859a and clinafloxacin (CI-960) against staphylococci-Reference-Cited by-同舟云学术

Bactericidal activities of DU-6859a and clinafloxacin (CI-960) against staphylococci

Published:1994-08 Issue:8 Volume:38 Page:1868-1870
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Forstall G J¹,Knapp C C¹,Washington J A¹

Affiliation:

1. Department of Clinical Pathology, Cleveland Clinic Foundation, Ohio 44195-5140.

Abstract

Time killing curves were calculated at concentrations of 2 and 8 times the MICs of DU-6859a and clinafloxacin against six isolates of Staphylococcus aureus. Both quinolones produced a decrease in the log10 CFU per milliliter of > or = 3 within 3 h at 2 and 8 times the MIC for the ciprofloxacin-susceptible isolates and at 8 times the MIC for the ciprofloxacin-resistant isolates; however, only 8 times the MIC of DU-6859a consistently prevented regrowth of all isolates after 24 h of incubation.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.38.8.1868

Reference9 articles.

1. In vitro antistaphylococcal activities of two investigative fluoroquinolones, CI-960 and WIN 57273, compared with ciprofloxacin, mupirocin (pseudomonic acid), and peptideclass antimicrobial agents;Aldridge K. E.;Antimicrob. Agents Chemother.,1992

2. Hooper D. C. and J. S. Wolfson. 1993. Mechanisms of quinolone action and bacterial killing p. 53-75. In D. C. Hooper and J. S. Wolfson (ed.) Quinolone antimicrobial agents. American Society for Microbiology Washington D.C.

3. CI-960, a novel fluoroquinolone, for therapy of experimental ciprofloxacin-susceptible and -resistant Staphylococcus aureus endocarditis;Kaatz G. W.;Antimicrob. Agents Chemother.,1992

4. Levin C. S. and J. T. Smith. 1988. Bactericidal mechanisms of ofloxacin. J. Antimicrob. Chemother. 22(Suppl. C):1-8.

5. Nakashima M. T. Uematsu M. Nakano K. Kosuge M. Tanaka and H. Hakusui. 1993. Program Abstr. 33rd Intersci. Conf. Antimicrob. Agents Chemother. abstr. 1004.

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effects of ABCB1 , UGT1A1 , and UGT1A9 Genetic Polymorphisms on the Pharmacokinetics of Sitafloxacin Granules in Healthy Subjects;Clinical Pharmacology in Drug Development;2020-07-20

2. Bacterial Infections in the Elderly Patient: Focus on Sitafloxacin;Clinical Medicine Insights: Therapeutics;2012-01

3. Sitafloxacin;Drugs in R & D;2003

4. Bacterial eradication by clinafloxacin, CI-990, and ciprofloxacin employing MBC test, in-vitro time-kill and in-vivo time-kill studies;Journal of Antimicrobial Chemotherapy;1998-06-01

5. Clinafloxacin (CI 960) is Superior to Standard Therapeutics in the Treatment of Murine Listeriosis and Salmonellosis;Zentralblatt für Bakteriologie;1997-10